Only a small percentage of primary and secondary liver tumours is suitable for surgical resection. Gene therapy
represents a novel strategy that seems to be effective both, in vitro and in vivo. The use of tumour suppressor gene
p53 therapy, suicide gene therapy, immune gene therapy and therapy with replication-competent oncolytic adenoviruses
in liver tumours already entered the first clinical trials. In patients with hepatocellular carcinoma, the first
clinical trials in phase I and II showed good tolerance and low toxicity to gene therapy. However, the clinical benefit
for the patients treated either with wild type p53 or E1B deleted adenoviruses were marginal.
gene therapy, liver tumours, clinical trial.